A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international...
Saved in:
| Published in | Vaccine Vol. 39; no. 45; pp. 6573 - 6584 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
29.10.2021
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D. |
|---|---|
| AbstractList | Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D. Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D. AbstractImproved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D. |
| Author | Krammer, Florian Kang, Gagandeep Gust, Ian Katz, Jacqueline Barclay, Wendy Osterholm, Michael T. Kraigsley, Alison M. Innis, Bruce Bresee, Joseph S. Cox, Rebecca Mehr, Angela J. Siqueira, Marilda Cowling, Benjamin Pitisuttithum, Punnee Cohen, Cheryl Weir, Jerry Friede, Martin H. Post, Diane Golding, Josephine P. Cavaleri, Marco Ampofo, William Rudenko, Larisa Ostrowsky, Julia T. Moore, Kristine A. Weller, Charlotte L. Hart, Peter J. Gellin, Bruce G. Moen, Ann |
| Author_xml | – sequence: 1 givenname: Kristine A. surname: Moore fullname: Moore, Kristine A. email: kamoore@umn.edu organization: Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA – sequence: 2 givenname: Julia T. surname: Ostrowsky fullname: Ostrowsky, Julia T. organization: Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA – sequence: 3 givenname: Alison M. surname: Kraigsley fullname: Kraigsley, Alison M. organization: Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA – sequence: 4 givenname: Angela J. surname: Mehr fullname: Mehr, Angela J. organization: Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA – sequence: 5 givenname: Joseph S. surname: Bresee fullname: Bresee, Joseph S. organization: The Global Funders Consortium for Universal Influenza Vaccine Development, The Task Force for Global Health, and the US Centers for Disease Control and Prevention, Atlanta, GA, USA – sequence: 6 givenname: Martin H. surname: Friede fullname: Friede, Martin H. organization: World Health Organization, Geneva, Switzerland – sequence: 7 givenname: Bruce G. surname: Gellin fullname: Gellin, Bruce G. organization: The Sabin Vaccine Institute, Washington, D.C., USA – sequence: 8 givenname: Josephine P. surname: Golding fullname: Golding, Josephine P. organization: Wellcome Trust, London, United Kingdom – sequence: 9 givenname: Peter J. surname: Hart fullname: Hart, Peter J. organization: Wellcome Trust, London, United Kingdom – sequence: 10 givenname: Ann surname: Moen fullname: Moen, Ann organization: World Health Organization, Geneva, Switzerland – sequence: 11 givenname: Charlotte L. surname: Weller fullname: Weller, Charlotte L. organization: Wellcome Trust, London, United Kingdom – sequence: 12 givenname: Michael T. surname: Osterholm fullname: Osterholm, Michael T. organization: Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA – sequence: 13 givenname: William surname: Ampofo fullname: Ampofo, William organization: University of Ghana, Accra, Ghana – sequence: 14 givenname: Wendy surname: Barclay fullname: Barclay, Wendy organization: Imperial College London, London, United Kingdom – sequence: 15 givenname: Marco surname: Cavaleri fullname: Cavaleri, Marco organization: European Medicines Agency, Amsterdam, the Netherlands – sequence: 16 givenname: Cheryl orcidid: 0000-0003-0376-2302 surname: Cohen fullname: Cohen, Cheryl organization: National Institute for Communicable Diseases and University of the Witwatersrand, Johannesburg, South Africa – sequence: 17 givenname: Benjamin surname: Cowling fullname: Cowling, Benjamin organization: University of Hong Kong, Hong Kong – sequence: 18 givenname: Rebecca orcidid: 0000-0002-8341-4078 surname: Cox fullname: Cox, Rebecca organization: University of Bergen, Bergen, Norway – sequence: 19 givenname: Ian surname: Gust fullname: Gust, Ian organization: University of Melbourne, Melbourne, Australia – sequence: 20 givenname: Bruce surname: Innis fullname: Innis, Bruce organization: PATH Center for Vaccine Innovation & Access, Washington, D.C., USA – sequence: 21 givenname: Gagandeep orcidid: 0000-0002-3656-564X surname: Kang fullname: Kang, Gagandeep organization: Christian Medical College, Vellore, India – sequence: 22 givenname: Jacqueline orcidid: 0000-0002-9817-4839 surname: Katz fullname: Katz, Jacqueline organization: US Centers for Disease Control & Prevention (Retired), Atlanta, GA, USA – sequence: 23 givenname: Florian surname: Krammer fullname: Krammer, Florian organization: Icahn School of Medicine at Mount Sinai, New York City, NY, USA – sequence: 24 givenname: Punnee orcidid: 0000-0003-3215-2183 surname: Pitisuttithum fullname: Pitisuttithum, Punnee organization: Mahidol University, Bangkok, Thailand – sequence: 25 givenname: Diane surname: Post fullname: Post, Diane organization: National Institutes of Health, Bethesda, MD, USA – sequence: 26 givenname: Larisa surname: Rudenko fullname: Rudenko, Larisa organization: Institute of Experimental Medicine, St. Petersburg, Russia – sequence: 27 givenname: Marilda orcidid: 0000-0003-4685-9817 surname: Siqueira fullname: Siqueira, Marilda organization: Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil – sequence: 28 givenname: Jerry surname: Weir fullname: Weir, Jerry organization: Food and Drug Administration, Silver Spring, MD, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34602302$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl9rFDEUxYNU7Lb6EZSAIPVh1ptkZyZTsaW0_oMFoSqILyGb3LHZziZrMrNSP71Zdu3DgqxPefmdk3vPuUfkwAePhDxlMGbAqlfz8Uob4zyOOXA2BjkGBg_IiMlaFLxk8oCMgFeTYsLg2yE5SmkOAKVgzSNyKCYVcAF8RL5f0GtMqKO5odpbeoUr7MJygb6nJ9cvrl7SGLRd6CVtQ6TOt92A_rem28_TKZ2GcOv8D9qHXzpa2t8gbYd-iPiYPGx1l_DJ9j0mX9-9_XL5oZh-ev_x8mJamFLyvqi5qEBLaYQB4BMUprKNNlbU1tQVk7zkTaktiFrOsJ1VdY215cYy0-R9ZrU4Jicb32UMPwdMvVq4ZLDrtMcwJMUrUUlWNrzcj5Z1A42csLXr8x10Hobo8yKZykNVTR42U8-21DBboFXL6BY63qm_AWeg3AAmhpQitvcIA7UuUs3VNku1LlKBVLnIrHu9ozOu170Lvo_adXvV5xs15txXDqNKxqE3aF1E0ysb3F6Hsx0H0znvjO5u8Q7TfRZMJa5AfV6f2vrSePYELmU2ePNvg_8Y4A_f3-NH |
| CitedBy_id | crossref_primary_10_1007_s12325_023_02770_0 crossref_primary_10_3390_cells10113067 crossref_primary_10_3390_vaccines11010180 crossref_primary_10_2174_1570178619666220919102545 crossref_primary_10_1186_s12889_024_18694_5 crossref_primary_10_1128_spectrum_00665_24 crossref_primary_10_1186_s12916_023_02830_w crossref_primary_10_1080_21645515_2024_2421096 crossref_primary_10_1038_s41577_024_01030_8 crossref_primary_10_1016_S1473_3099_22_00056_1 crossref_primary_10_1186_s12916_025_03973_8 crossref_primary_10_1016_j_vaccine_2024_126408 crossref_primary_10_1093_oxfimm_iqac004 crossref_primary_10_4103_ijmr_ijmr_184_23 crossref_primary_10_1007_s00705_024_06210_4 crossref_primary_10_3389_fphar_2024_1404021 crossref_primary_10_3390_vaccines10040589 crossref_primary_10_3389_fpubh_2023_1331136 crossref_primary_10_1016_j_vaccine_2025_126847 crossref_primary_10_1016_j_jconrel_2022_01_046 crossref_primary_10_1007_s12325_023_02610_1 crossref_primary_10_1016_j_vaccine_2023_02_032 crossref_primary_10_1111_irv_70025 crossref_primary_10_1016_j_jvacx_2023_100402 crossref_primary_10_3390_vaccines11101573 crossref_primary_10_1002_cpt_2889 crossref_primary_10_3390_vaccines11101601 crossref_primary_10_55544_jrasb_3_4_20 crossref_primary_10_1007_s12325_023_02432_1 crossref_primary_10_2174_0118743064319029240815074449 crossref_primary_10_1093_discim_kyad030 crossref_primary_10_1186_s13561_024_00535_1 crossref_primary_10_18332_popmed_177169 crossref_primary_10_1016_j_vaccine_2022_08_071 crossref_primary_10_1016_j_virol_2024_110162 crossref_primary_10_1371_journal_ppat_1010106 crossref_primary_10_3390_vaccines12091036 crossref_primary_10_3389_fimmu_2022_974433 crossref_primary_10_1016_j_vaccine_2023_08_031 crossref_primary_10_3390_joitmc8010005 crossref_primary_10_1016_S1473_3099_23_00294_3 crossref_primary_10_3390_vaccines11030501 crossref_primary_10_1038_s41598_023_28295_8 crossref_primary_10_3390_vaccines10050709 |
| Cites_doi | 10.1093/infdis/jiz043 10.1101/cshperspect.a038471 10.1016/j.chom.2019.04.003 10.3390/pathogens3040845 10.1128/JVI.00797-19 10.1073/pnas.1816300116 10.1073/pnas.1712377114 10.3390/vaccines6020019 10.1056/NEJMp2005630 10.1093/infdis/jiy696 10.1016/j.vaccine.2020.12.018 10.1001/jama.2020.25384 10.1016/j.coviro.2016.12.004 10.1093/infdis/jiz024 10.1016/j.vaccine.2017.09.048 10.1038/s41598-019-39276-1 10.3390/vaccines6030058 10.1016/j.vaccine.2019.06.080 10.1056/NEJMoa2034577 10.1080/14760584.2017.1334554 10.1016/j.vaccine.2020.01.101 10.1038/s41577-019-0143-6 10.1089/hs.2020.0043 10.1016/j.vaccine.2020.04.069 10.1038/d41586-021-00340-4 10.1371/journal.ppat.1008583 10.3389/fimmu.2019.01605 10.1016/j.vaccine.2019.06.053 10.3390/vaccines8030361 10.3390/vaccines8030434 10.1080/21645515.2017.1415684 10.3390/microorganisms8111745 10.1093/infdis/jiz017 10.1016/j.vaccine.2018.11.037 10.1186/s12889-019-6713-5 10.1016/j.it.2017.08.003 10.1093/aje/kwy145 10.1016/j.chom.2018.06.016 10.1128/mBio.02332-17 10.1080/21645515.2017.1423152 10.1111/j.1750-2659.2011.00277.x 10.1093/infdis/jiy711 10.1038/nm.3350 10.1093/infdis/jis535 10.1016/j.vaccine.2021.03.038 10.1126/scitranslmed.aaw2888 10.3201/eid2502.180359 10.1016/j.vaccine.2011.11.092 10.1016/j.coi.2018.05.010 10.1093/infdis/jiy103 10.1101/cshperspect.a040964 10.1093/cid/ciz676 10.1038/s41467-019-09652-6 10.2139/ssrn.3586996 10.3390/pharmaceutics13010068 10.1586/erv.13.35 10.3390/vaccines9010026 10.3390/vaccines8030409 10.3389/fimmu.2018.00600 10.3389/fimmu.2019.02997 10.1093/infdis/jiz433 10.1093/infdis/jiy745 10.1080/21645515.2018.1462639 10.1073/pnas.1920321117 10.1093/cid/ciaa706 10.1038/s41591-018-0340-z 10.1016/S0140-6736(17)33293-2 10.1016/j.jcv.2019.08.009 10.1111/irv.12706 10.1093/infdis/jiy728 10.1016/j.coviro.2011.08.002 10.1016/j.vaccine.2018.10.024 10.1093/jpids/piy057 10.1016/j.vaccine.2014.01.053 |
| ContentType | Journal Article |
| Contributor | Cox, Rebecca Krammer, Florian Siqueira, Marilda Kang, Gagandeep Cowling, Benjamin Pitisuttithum, Punnee Cohen, Cheryl Weir, Jerry Gust, Ian Katz, Jacqueline Post, Diane Cavaleri, Marco Barclay, Wendy Ampofo, William Rudenko, Larisa Innis, Bruce |
| Contributor_xml | – sequence: 1 givenname: William surname: Ampofo fullname: Ampofo, William organization: University of Ghana, Accra, Ghana – sequence: 2 givenname: Wendy surname: Barclay fullname: Barclay, Wendy organization: Imperial College London, London, United Kingdom – sequence: 3 givenname: Marco surname: Cavaleri fullname: Cavaleri, Marco organization: European Medicines Agency, Amsterdam, the Netherlands – sequence: 4 givenname: Cheryl surname: Cohen fullname: Cohen, Cheryl organization: National Institute for Communicable Diseases and University of the Witwatersrand, Johannesburg, South Africa – sequence: 5 givenname: Benjamin surname: Cowling fullname: Cowling, Benjamin organization: University of Hong Kong, Hong Kong – sequence: 6 givenname: Rebecca surname: Cox fullname: Cox, Rebecca organization: University of Bergen, Bergen, Norway – sequence: 7 givenname: Ian surname: Gust fullname: Gust, Ian organization: University of Melbourne, Melbourne, Australia – sequence: 8 givenname: Bruce surname: Innis fullname: Innis, Bruce organization: PATH Center for Vaccine Innovation & Access, Washington, D.C., USA – sequence: 9 givenname: Gagandeep surname: Kang fullname: Kang, Gagandeep organization: Christian Medical College, Vellore, India – sequence: 10 givenname: Jacqueline surname: Katz fullname: Katz, Jacqueline organization: US Centers for Disease Control & Prevention (Retired), Atlanta, GA, USA – sequence: 11 givenname: Florian surname: Krammer fullname: Krammer, Florian organization: Icahn School of Medicine at Mount Sinai, New York City, NY, USA – sequence: 12 givenname: Punnee surname: Pitisuttithum fullname: Pitisuttithum, Punnee organization: Mahidol University, Bangkok, Thailand – sequence: 13 givenname: Diane surname: Post fullname: Post, Diane organization: National Institutes of Health, Bethesda, MD, USA – sequence: 14 givenname: Larisa surname: Rudenko fullname: Rudenko, Larisa organization: Institute of Experimental Medicine, St. Petersburg, Russia – sequence: 15 givenname: Marilda surname: Siqueira fullname: Siqueira, Marilda organization: Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil – sequence: 16 givenname: Jerry surname: Weir fullname: Weir, Jerry organization: Food and Drug Administration, Silver Spring, MD, USA |
| Copyright | 2021 The Authors The Authors Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. 2021. The Authors |
| Copyright_xml | – notice: 2021 The Authors – notice: The Authors – notice: Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: 2021. The Authors |
| CorporateAuthor | The Influenza Vaccines R&D Roadmap Taskforce Influenza Vaccines R&D Roadmap Taskforce |
| CorporateAuthor_xml | – name: The Influenza Vaccines R&D Roadmap Taskforce – name: Influenza Vaccines R&D Roadmap Taskforce |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2021.08.010 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) ProQuest Nursing & Allied Health Database (NC LIVE) Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest Research Library (NC LIVE) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE Research Library Prep MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology Public Health |
| EISSN | 1873-2518 |
| EndPage | 6584 |
| ExternalDocumentID | 34602302 10_1016_j_vaccine_2021_08_010 S0264410X21010288 1_s2_0_S0264410X21010288 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Wellcome Trust – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP 6I. AAFTH AAIAV ABLVK ABYKQ AESVU EFLBG LCYCR QYZTP AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c582t-72360a88c3c0024e3c6d9acd37dc761825295ad0378befb677e7d2cd1c9005b73 |
| IEDL.DBID | 7X7 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Tue Aug 05 10:15:21 EDT 2025 Fri Jul 11 01:03:40 EDT 2025 Wed Aug 13 03:33:07 EDT 2025 Mon Jul 21 06:03:13 EDT 2025 Tue Jul 01 01:07:03 EDT 2025 Thu Apr 24 22:58:10 EDT 2025 Fri Feb 23 02:46:58 EST 2024 Tue Feb 25 20:05:40 EST 2025 Tue Aug 26 16:34:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 45 |
| Keywords | LAIV CEPI IVR Universal influenza vaccines Seasonal influenza vaccines COBRA ABS HVAC CARB-X ME&A CIDRAP FVVA CHIVIM ADCC WHO CIVICs SME LMICs NIAID EU HAI R&D Broadly protective influenza vaccines Roadmap ACT NA Influenza IIV GISRS HA Pandemic preparedness US National Institute of Allergy and Infectious Diseases hemagglutinin inactivated influenza vaccines heating, ventilation, and air conditioning computationally optimized broadly reactive antigen biopharmaceutical accelerator for combating antibiotic resistant bacteria World Health Organization Global Influenza Surveillance and Response System antibody-dependent cellular cytotoxicity neuraminidase Collaborative Influenza Vaccine Innovation Centers Research and Development Access to COVID-19 Tools controlled human influenza virus infection model Center for Infectious Disease Research and Policy live-attenuated influenza vaccines monitoring, evaluation, and adjustment Access and Benefit Sharing low- and middle-income countries full value of vaccine assessment subject matter expert Influenza Vaccines Research and Development (R&D) Roadmap European Union Coalition for Epidemic Preparedness Innovations hemagglutination-inhibition |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c582t-72360a88c3c0024e3c6d9acd37dc761825295ad0378befb677e7d2cd1c9005b73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-0376-2302 0000-0002-9817-4839 0000-0003-3215-2183 0000-0003-4685-9817 0000-0002-3656-564X 0000-0002-8341-4078 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X21010288 |
| PMID | 34602302 |
| PQID | 2582569024 |
| PQPubID | 105530 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2636815925 proquest_miscellaneous_2579098417 proquest_journals_2582569024 pubmed_primary_34602302 crossref_primary_10_1016_j_vaccine_2021_08_010 crossref_citationtrail_10_1016_j_vaccine_2021_08_010 elsevier_sciencedirect_doi_10_1016_j_vaccine_2021_08_010 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X21010288 elsevier_clinicalkey_doi_10_1016_j_vaccine_2021_08_010 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-29 |
| PublicationDateYYYYMMDD | 2021-10-29 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Guthmiller, Wilson (b0340) 2018; 53 Porter, Goldin, Lafond, Hedman, Ungkuldee, Kurzum (b0030) 2009; 2019 Sridhar, Begom, Bermingham, Hoschler, Adamson, Carman (b0425) 2013; 19 GISAID. GISAID - Mission 2021. Innis, Scorza, Blum, Jain, Aguilar, Post (b0460) 2019; 37 Linderman, Ellebedy, Davis, Eberhardt, Antia, Ahmed (b0280) 2020 Calzas, Chevalier (b0245) 2019; 10 Plotkin (b0330) 2018; 7 WHO. Global Influenza Strategy 2019-2030. WHO; 2019. Zost, Parkhouse, Gumina, Kim, Diaz Perez, Wilson (b0200) 2017; 114 Bill and Melinda Gates Foundation. Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development; 2018. Lopez, Legge (b0210) 2020; 8 (accessed May 2, 2021). Robinson (b0490) 2021 Wei, Crank, Shiver, Graham, Mascola, Nabel (b0110) 2020 McMillan, Young, Watterson, Chappell (b0095) 2021; 9 Zhu, Dong, Wei, Wang (b0380) 2021; 13 Li, Zhao, Li, Chen (b0390) 2021; 9 . Kanekiyo, Ellis, King (b0400) 2019; 219 Gessner, Kaslow, Louis, Neuzil, O’Brien, Picot (b0495) 2017; 35 Madsen, Cox (b0315) 2020; 8 Burton, Topol (b0520) 2021; 590 Erbelding, Post, Stemmy, Roberts, Augustine, Ferguson (b0080) 2018; 218 Moderna. Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines | Moderna, Inc.; 2021 Amitai A, Sangesland M, Barnes RM, Rohrer D, Lonberg N, Lingwood D, et al. Defining and manipulating B cell immunodominance hierarchies to elicit broadly neutralizing antibody responses against influenza virus. Cell Syst 2020:S2405471220303355. Richards KA, Shannon I, Treanor JJ, Yang H, Nayak JL, Sant AJ. Evidence that blunted CD4 T cells responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects. J Infect Dis n.d. Jang, Seong (b0420) 2020 World Health Organization. WHO preferred product characteristics for next generation influenza vaccines; 2017. Hughes, Reed, Flannery, Garg, Singleton, Fry (b0360) 2020; 70 Iuliano, Roguski, Chang, Muscatello, Palekar, Tempia (b0035) 2018; 391 Baselga-Moreno, Trushakova, McNeil, Sominina, Nunes, Draganescu (b0355) 2019; 19 Dhakal, Klein (b0015) 2019 [accessed May 3, 2021]. Henry, Palm, Krammer, Wilson (b0345) 2018; 39 CDC. CDC Seasonal Flu Vaccine Effectiveness Studies | CDC 2019. Secretariat for the Convention on Biological Diversity. The Nagoya Protocol on Access and Benefit-sharing 2021. Gianchecchi, Torelli, Montomoli (b0325) 2019 Eichelberger, Monto (b0365) 2019; 219 Reber, Katz (b0295) 2013; 12 Krammer, Weir, Engelhardt, Katz, Cox (b0305) 2020; 14 Worobey, Plotkin, Hensley (b0265) 2020 Lane, Gordon, Jiang, Leitner, Pickett, Stemmy (b0450) 2020; 38 Global Funders Consortium for Universal Influenza Vaccine Development. Meeting Report, November 2-3, 2017 n.d. Wraith, Nachbagauer, Balmaseda, Stadlbauer, Ojeda, Rajabhathor (b0300) 2020; 38 Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, et al. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis 2020:ciaa706. Rosa, Prazeres, Azevedo, Marques (b0105) 2021 Belongia, Skowronski, McLean, Chambers, Sundaram, Serres (b0270) 2017; 16 CARB-X. CARB-X. Carb-X n.d. Coughlan, Palese (b0320) 2018; 24 Margine, Krammer (b0445) 2014; 3 International Energy Agency. Energy technology roadmaps: a guide to development and implementation; 2014. Viboud, Gostic, Nelson, Price, Perofsky, Sun (b0170) 2020; 16 Billington, Deschamps, Erck, Gerberding, Hanon, Ivol (b0045) 2020; 18 IVR Roadmap Development Team. Influenza Vaccines R&D Roadmap. CIDRAP. n.d. Morens, Taubenberger (b0205) 2019; 219 [accessed February 18, 2021]. Zost, Wu, Hensley, Wilson (b0020) 2019; 219 [accessed May 2, 2021]. Mihigo, Torrealba, Coninx, Nshimirimana, Kieny, Carrasco (b0055) 2012; 206 Ortiz, Neuzil (b0025) 2019; 219 European External Action Service (EEAS). EU – India joint call “Towards a Next Generation Influenza Vaccine to Protect Citizens Worldwide.” EEAS - European External Action Service - European Union External Action. n.d. Bresee, McKinlay, Abramson, Klugman, Wairagkar (b0130) 2019; 37 Krammer (b0225) 2019; 19 Jansen, Gerlach, Elbahesh, Rimmelzwaan, Saletti (b0290) 2019; 119 Jorquera, Mishin, Chesnokov, Nguyen, Mann, Garten (b0175) 2019; 9 Bartley, Cadar, Martin (b0085) 2021 Navarro-Torné, Hanrahan, Kerstiëns, Aguar, Matthiessen (b0500) 2019; 25 Tregoning, Russell, Kinnear (b0385) 2018; 14 NIAID. The Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. About CIVICs. n.d. Cobey, Hensley (b0335) 2017; 22 Ranjeva, Subramanian, Fang, Leung, Ip, Perera (b0260) 2019; 10 Kanekiyo, Graham (b0395) 2020 Angeletti, Kosik, Santos, Yewdell, Boudreau, Mallajosyula (b0230) 2019; 116 Ropero-Álvarez, Whittembury, Kurtis, dos Santos, Danovaro-Holliday, Ruiz-Matus (b0060) 2012; 30 Krammer, Fouchier, Eichelberger, Webby, Shaw-Saliba, Wan (b0375) 2018; 9 Lim, Leung, Sullivan, Tchetgen Tchetgen, Cowling (b0310) 2019 Sparrow, Wood, Chadwick, Newall, Torvaldsen, Moen (b0475) 2021; 39 Mathew, Angeletti (b0240) 2020; 10 Kumar, Meldgaard, Bertholet (b0090) 2018; 9 [accessed May 1, 2021]. Yamayoshi, Kawaoka (b0405) 2019; 25 University of Oxford. Human challenge trial launches to study immune response to COVID-19 | University of Oxford n.d. Ampofo, Baylor, Cobey, Cox, Daves, Edwards (b0165) 2012; 6 Agor, Özaltın (b0180) 2018; 14 Crank, Mascola, Graham (b0185) 2019; 219 CEPI. CEPI | New Vaccines For A Safer World. Coalition for Epidemic Preparedness Innovations n.d. Arevalo, Sage, Bolton, Eilola, Jones, Kormuth (b0255) 2020 Sabin-Aspen Vaccine Science Policy Group. Accelerating the Development of a Universal Influenza Vaccine. Aspen Institute and Sabin Vaccine Institute; 2019. Topham, DeDiego, Nogales, Sangster, Sant (b0220) 2019 Krammer, Palese (b0430) 2019; 219 Harding, Heaton (b0195) 2018; 6 CDC. Selecting Viruses for the Seasonal Flu Vaccine. Centers for Disease Control and Prevention; 2020. Cortese, Sherman, Rouphael, Pulendran (b0215) 2020 Allen, Ross (b0190) 2018; 14 Bajic, Maron, Adachi, Onodera, McCarthy, McGee (b0235) 2019 Imperial College London. First volunteers on COVID-19 human challenge study leave quarantine | Imperial News | Imperial College London. Imperial News n.d. WHO. Global Influenza Surveillance and Response System (GISRS). Global Influenza Surveillance and Response System (GISRS) n.d. Broutet, Fruth, Deal, Gottlieb, Rees (b0140) 2014; 32 D’Alessio, Koopman, Houard, Remarque, Stockhofe, Engelhardt (b0440) 2018; 36 (accessed February 18, 2021). Bouvier (b0435) 2018; 6 Polack, Thomas, Kitchin, Judith Absalon, Gurtman, Lockhart (b0160) 2020; 383 Innis, Berlanda Scorza, Blum, Jain, Older Aguilar, Post (b0455) 2019; 37 Rappuoli R, Black S, Bloom DE. Vaccines and global health: in search of a sustainable model in vaccine development and delivery. Sci Transl Med 2019;11(497):eaaw2888. doi: 10.1126/scitranslmed.aaw2888. Rockman, Laurie, Parkes, Wheatley, Barr (b0100) 2020; 8 Giurgea, Morens, Taubenberger, Memoli (b0370) 2020; 8 Broadbent, Subbarao (b0050) 2011; 1 Novavax. Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure; 2020. De Jong, Aartse, Van Gils, Eggink (b0415) 2020 Lurie, Saville, Hatchett, Halton (b0525) 2020; 382 Epstein (b0250) 2018 Worobey (10.1016/j.vaccine.2021.08.010_b0265) 2020 Madsen (10.1016/j.vaccine.2021.08.010_b0315) 2020; 8 Sparrow (10.1016/j.vaccine.2021.08.010_b0475) 2021; 39 Angeletti (10.1016/j.vaccine.2021.08.010_b0230) 2019; 116 Hughes (10.1016/j.vaccine.2021.08.010_b0360) 2020; 70 10.1016/j.vaccine.2021.08.010_b0145 Ropero-Álvarez (10.1016/j.vaccine.2021.08.010_b0060) 2012; 30 Viboud (10.1016/j.vaccine.2021.08.010_b0170) 2020; 16 Jang (10.1016/j.vaccine.2021.08.010_b0420) 2020 Krammer (10.1016/j.vaccine.2021.08.010_b0430) 2019; 219 Bresee (10.1016/j.vaccine.2021.08.010_b0130) 2019; 37 Porter (10.1016/j.vaccine.2021.08.010_b0030) 2009; 2019 Calzas (10.1016/j.vaccine.2021.08.010_b0245) 2019; 10 Dhakal (10.1016/j.vaccine.2021.08.010_b0015) 2019 Iuliano (10.1016/j.vaccine.2021.08.010_b0035) 2018; 391 Mathew (10.1016/j.vaccine.2021.08.010_b0240) 2020; 10 Krammer (10.1016/j.vaccine.2021.08.010_b0375) 2018; 9 D’Alessio (10.1016/j.vaccine.2021.08.010_b0440) 2018; 36 Lane (10.1016/j.vaccine.2021.08.010_b0450) 2020; 38 Crank (10.1016/j.vaccine.2021.08.010_b0185) 2019; 219 Li (10.1016/j.vaccine.2021.08.010_b0390) 2021; 9 10.1016/j.vaccine.2021.08.010_b0275 Ortiz (10.1016/j.vaccine.2021.08.010_b0025) 2019; 219 10.1016/j.vaccine.2021.08.010_b0155 Plotkin (10.1016/j.vaccine.2021.08.010_b0330) 2018; 7 Innis (10.1016/j.vaccine.2021.08.010_b0460) 2019; 37 10.1016/j.vaccine.2021.08.010_b0150 Margine (10.1016/j.vaccine.2021.08.010_b0445) 2014; 3 Billington (10.1016/j.vaccine.2021.08.010_b0045) 2020; 18 Polack (10.1016/j.vaccine.2021.08.010_b0160) 2020; 383 Broadbent (10.1016/j.vaccine.2021.08.010_b0050) 2011; 1 Guthmiller (10.1016/j.vaccine.2021.08.010_b0340) 2018; 53 Bartley (10.1016/j.vaccine.2021.08.010_b0085) 2021 Zost (10.1016/j.vaccine.2021.08.010_b0020) 2019; 219 Topham (10.1016/j.vaccine.2021.08.010_b0220) 2019 McMillan (10.1016/j.vaccine.2021.08.010_b0095) 2021; 9 10.1016/j.vaccine.2021.08.010_b0040 Wei (10.1016/j.vaccine.2021.08.010_b0110) 2020 10.1016/j.vaccine.2021.08.010_b0285 Mihigo (10.1016/j.vaccine.2021.08.010_b0055) 2012; 206 Gessner (10.1016/j.vaccine.2021.08.010_b0495) 2017; 35 Lim (10.1016/j.vaccine.2021.08.010_b0310) 2019 Yamayoshi (10.1016/j.vaccine.2021.08.010_b0405) 2019; 25 Jorquera (10.1016/j.vaccine.2021.08.010_b0175) 2019; 9 Sridhar (10.1016/j.vaccine.2021.08.010_b0425) 2013; 19 Epstein (10.1016/j.vaccine.2021.08.010_b0250) 2018 Belongia (10.1016/j.vaccine.2021.08.010_b0270) 2017; 16 Reber (10.1016/j.vaccine.2021.08.010_b0295) 2013; 12 Kumar (10.1016/j.vaccine.2021.08.010_b0090) 2018; 9 Gianchecchi (10.1016/j.vaccine.2021.08.010_b0325) 2019 Lurie (10.1016/j.vaccine.2021.08.010_b0525) 2020; 382 Eichelberger (10.1016/j.vaccine.2021.08.010_b0365) 2019; 219 Baselga-Moreno (10.1016/j.vaccine.2021.08.010_b0355) 2019; 19 Erbelding (10.1016/j.vaccine.2021.08.010_b0080) 2018; 218 Rockman (10.1016/j.vaccine.2021.08.010_b0100) 2020; 8 Ranjeva (10.1016/j.vaccine.2021.08.010_b0260) 2019; 10 10.1016/j.vaccine.2021.08.010_b0505 Bajic (10.1016/j.vaccine.2021.08.010_b0235) 2019 Harding (10.1016/j.vaccine.2021.08.010_b0195) 2018; 6 Cortese (10.1016/j.vaccine.2021.08.010_b0215) 2020 10.1016/j.vaccine.2021.08.010_b0465 Navarro-Torné (10.1016/j.vaccine.2021.08.010_b0500) 2019; 25 10.1016/j.vaccine.2021.08.010_b0065 10.1016/j.vaccine.2021.08.010_b0070 Allen (10.1016/j.vaccine.2021.08.010_b0190) 2018; 14 Krammer (10.1016/j.vaccine.2021.08.010_b0305) 2020; 14 Innis (10.1016/j.vaccine.2021.08.010_b0455) 2019; 37 10.1016/j.vaccine.2021.08.010_b0515 Wraith (10.1016/j.vaccine.2021.08.010_b0300) 2020; 38 10.1016/j.vaccine.2021.08.010_b0510 10.1016/j.vaccine.2021.08.010_b0115 Kanekiyo (10.1016/j.vaccine.2021.08.010_b0400) 2019; 219 Henry (10.1016/j.vaccine.2021.08.010_b0345) 2018; 39 10.1016/j.vaccine.2021.08.010_b0470 10.1016/j.vaccine.2021.08.010_b0075 10.1016/j.vaccine.2021.08.010_b0350 Kanekiyo (10.1016/j.vaccine.2021.08.010_b0395) 2020 10.1016/j.vaccine.2021.08.010_b0125 Lopez (10.1016/j.vaccine.2021.08.010_b0210) 2020; 8 10.1016/j.vaccine.2021.08.010_b0005 10.1016/j.vaccine.2021.08.010_b0485 Burton (10.1016/j.vaccine.2021.08.010_b0520) 2021; 590 10.1016/j.vaccine.2021.08.010_b0480 Tregoning (10.1016/j.vaccine.2021.08.010_b0385) 2018; 14 Bouvier (10.1016/j.vaccine.2021.08.010_b0435) 2018; 6 10.1016/j.vaccine.2021.08.010_b0120 Linderman (10.1016/j.vaccine.2021.08.010_b0280) 2020 Jansen (10.1016/j.vaccine.2021.08.010_b0290) 2019; 119 Agor (10.1016/j.vaccine.2021.08.010_b0180) 2018; 14 Arevalo (10.1016/j.vaccine.2021.08.010_b0255) 2020 Cobey (10.1016/j.vaccine.2021.08.010_b0335) 2017; 22 Giurgea (10.1016/j.vaccine.2021.08.010_b0370) 2020; 8 Zost (10.1016/j.vaccine.2021.08.010_b0200) 2017; 114 Morens (10.1016/j.vaccine.2021.08.010_b0205) 2019; 219 Zhu (10.1016/j.vaccine.2021.08.010_b0380) 2021; 13 Krammer (10.1016/j.vaccine.2021.08.010_b0225) 2019; 19 Broutet (10.1016/j.vaccine.2021.08.010_b0140) 2014; 32 10.1016/j.vaccine.2021.08.010_b0135 10.1016/j.vaccine.2021.08.010_b0410 10.1016/j.vaccine.2021.08.010_b0010 Robinson (10.1016/j.vaccine.2021.08.010_b0490) 2021 Ampofo (10.1016/j.vaccine.2021.08.010_b0165) 2012; 6 Rosa (10.1016/j.vaccine.2021.08.010_b0105) 2021 Coughlan (10.1016/j.vaccine.2021.08.010_b0320) 2018; 24 De Jong (10.1016/j.vaccine.2021.08.010_b0415) 2020 |
| References_xml | – volume: 19 start-page: 487 year: 2019 ident: b0355 article-title: Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) publication-title: BMC Public Health – reference: GISAID. GISAID - Mission 2021. – start-page: a038729 year: 2019 ident: b0220 article-title: Immunity to influenza infection in humans publication-title: Cold Spring Harb Perspect Med – volume: 25 start-page: 212 year: 2019 end-page: 220 ident: b0405 article-title: Current and future influenza vaccines publication-title: Nat Med – volume: 219 start-page: S107 year: 2019 end-page: S109 ident: b0185 article-title: Preparing for the next influenza pandemic: the development of a universal influenza vaccine publication-title: J Infect Dis – volume: 37 start-page: 211 year: 2019 end-page: 213 ident: b0130 article-title: Global funders consortium for universal influenza vaccine development publication-title: Vaccine – volume: 36 start-page: 6895 year: 2018 end-page: 6901 ident: b0440 article-title: Workshop report: experimental animal models for universal influenza vaccines publication-title: Vaccine – reference: Sabin-Aspen Vaccine Science Policy Group. Accelerating the Development of a Universal Influenza Vaccine. Aspen Institute and Sabin Vaccine Institute; 2019. – volume: 219 start-page: S5 year: 2019 end-page: S13 ident: b0205 article-title: Making universal influenza vaccines: lessons from the 1918 pandemic publication-title: J Infect Dis – reference: Rappuoli R, Black S, Bloom DE. Vaccines and global health: in search of a sustainable model in vaccine development and delivery. Sci Transl Med 2019;11(497):eaaw2888. doi: 10.1126/scitranslmed.aaw2888. – volume: 9 start-page: 26 year: 2021 ident: b0095 article-title: The next generation of influenza vaccines: towards a universal solution publication-title: Vaccines – volume: 37 start-page: 4823 year: 2019 end-page: 4829 ident: b0455 article-title: Meeting report: convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity publication-title: Vaccine – volume: 219 start-page: S75 year: 2019 end-page: S80 ident: b0365 article-title: Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection publication-title: J Infect Dis – reference: Secretariat for the Convention on Biological Diversity. The Nagoya Protocol on Access and Benefit-sharing 2021. – start-page: 1 year: 2021 end-page: 11 ident: b0085 article-title: Better, faster, stronger: mRNA vaccines show promise for influenza vaccination in older adults publication-title: Immunol Invest – volume: 8 start-page: 1745 year: 2020 ident: b0100 article-title: New technologies for influenza vaccines publication-title: Microorganisms – reference: (accessed February 18, 2021). – reference: Imperial College London. First volunteers on COVID-19 human challenge study leave quarantine | Imperial News | Imperial College London. Imperial News n.d. – volume: 10 start-page: 1660 year: 2019 ident: b0260 article-title: Age-specific differences in the dynamics of protective immunity to influenza publication-title: Nat Commun – volume: 3 start-page: 845 year: 2014 end-page: 874 ident: b0445 article-title: Animal models for influenza viruses: implications for universal vaccine development publication-title: Pathogens – volume: 6 start-page: 142 year: 2012 end-page: 152 ident: b0165 article-title: Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 publication-title: Influenza Other Respir Viruses – volume: 14 start-page: 678 year: 2018 end-page: 683 ident: b0180 article-title: Models for predicting the evolution of influenza to inform vaccine strain selection publication-title: Hum Vaccin Immunother – volume: 38 start-page: 4221 year: 2020 end-page: 4225 ident: b0300 article-title: Antibody responses to influenza A(H1N1)pdm infection publication-title: Vaccine – reference: University of Oxford. Human challenge trial launches to study immune response to COVID-19 | University of Oxford n.d. – volume: 9 start-page: 1 year: 2019 end-page: 16 ident: b0175 article-title: Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011–2018 publication-title: Sci Rep – volume: 206 start-page: S22 year: 2012 end-page: S28 ident: b0055 article-title: 2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa—successes and challenges publication-title: J Infect Dis – year: 2019 ident: b0235 article-title: Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope publication-title: Cell Host Microbe – reference: WHO. Global Influenza Surveillance and Response System (GISRS). Global Influenza Surveillance and Response System (GISRS) n.d. – year: 2021 ident: b0490 article-title: Funding of pharmaceutical innovation during and after the COVID-19 pandemic publication-title: JAMA – reference: [accessed February 18, 2021]. – reference: Richards KA, Shannon I, Treanor JJ, Yang H, Nayak JL, Sant AJ. Evidence that blunted CD4 T cells responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects. J Infect Dis n.d. – reference: (accessed May 2, 2021). – year: 2020 ident: b0255 article-title: Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies publication-title: PNAS – volume: 8 start-page: 409 year: 2020 ident: b0370 article-title: Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine publication-title: Vaccines – volume: 9 start-page: e02332 year: 2018 end-page: e2417 ident: b0375 article-title: NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? publication-title: MBio – volume: 219 start-page: S38 year: 2019 end-page: S45 ident: b0020 article-title: Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens publication-title: J Infect Dis – volume: 6 start-page: 19 year: 2018 ident: b0195 article-title: Efforts to improve the seasonal influenza vaccine publication-title: Vaccines – reference: World Health Organization. WHO preferred product characteristics for next generation influenza vaccines; 2017. – volume: 39 start-page: 512 year: 2021 end-page: 520 ident: b0475 article-title: Global production capacity of seasonal and pandemic influenza vaccines in 2019 publication-title: Vaccine – volume: 116 start-page: 13474 year: 2019 end-page: 13479 ident: b0230 article-title: Outflanking immunodominance to target subdominant broadly neutralizing epitopes publication-title: PNAS – volume: 114 start-page: 12578 year: 2017 end-page: 12583 ident: b0200 article-title: Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains publication-title: Proc Natl Acad Sci – reference: Global Funders Consortium for Universal Influenza Vaccine Development. Meeting Report, November 2-3, 2017 n.d. – volume: 7 start-page: 178 year: 2018 end-page: 180 ident: b0330 article-title: The influenza vaccine mess publication-title: J Pediatr Infectious Dis Soc – start-page: 1 year: 2020 end-page: 14 ident: b0110 article-title: Next-generation influenza vaccines: opportunities and challenges publication-title: Nat Rev Drug Discovery – reference: NIAID. The Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. About CIVICs. n.d. – volume: 219 start-page: S88 year: 2019 end-page: S96 ident: b0400 article-title: New vaccine design and delivery technologies publication-title: J Infect Dis – volume: 8 start-page: 361 year: 2020 ident: b0315 article-title: Prospects and challenges in the development of universal influenza vaccines publication-title: Vaccines – volume: 19 start-page: 1305 year: 2013 end-page: 1312 ident: b0425 article-title: Cellular immune correlates of protection against symptomatic pandemic influenza publication-title: Nat Med – volume: 16 year: 2020 ident: b0170 article-title: Beyond clinical trials: evolutionary and epidemiological considerations for development of a universal influenza vaccine publication-title: PLoS Pathog – reference: [accessed May 2, 2021]. – volume: 38 start-page: 2751 year: 2020 end-page: 2757 ident: b0450 article-title: Workshop report: optimization of animal models to better predict influenza vaccine efficacy publication-title: Vaccine – year: 2018 ident: b0250 article-title: Universal influenza vaccines: progress in achieving broad cross-protection in vivo publication-title: Am J Epidemiol – reference: Bill and Melinda Gates Foundation. Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development; 2018. – volume: 24 start-page: 18 year: 2018 end-page: 24 ident: b0320 article-title: Overcoming barriers in the path to a universal influenza virus vaccine publication-title: Cell Host Microbe – start-page: a038596 year: 2020 ident: b0215 article-title: Systems biological analysis of immune response to influenza vaccination publication-title: Cold Spring Harb Perspect Med – volume: 1 start-page: 254 year: 2011 end-page: 262 ident: b0050 article-title: Influenza virus vaccines: lessons from the 2009 H1N1 pandemic publication-title: Curr Opin Virol – start-page: 1 year: 2020 end-page: 15 ident: b0420 article-title: Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection publication-title: Expert Opin Drug Discov – volume: 12 start-page: 519 year: 2013 end-page: 536 ident: b0295 article-title: Immunological assessment of influenza vaccines and immune correlates of protection publication-title: Expert Rev Vac – volume: 382 start-page: 1969 year: 2020 end-page: 1973 ident: b0525 article-title: Developing Covid-19 vaccines at pandemic speed publication-title: N Engl J Med – volume: 25 year: 2019 ident: b0500 article-title: Public health-driven research and innovation for next-generation influenza vaccines, European Union publication-title: Emerg Infect Dis – reference: Novavax. Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure; 2020. – start-page: a040964 year: 2020 ident: b0280 article-title: Influenza immunization in the context of preexisting immunity publication-title: Cold Spring Harb Perspect Med – reference: CDC. CDC Seasonal Flu Vaccine Effectiveness Studies | CDC 2019. – reference: International Energy Agency. Energy technology roadmaps: a guide to development and implementation; 2014. – volume: 590 start-page: 386 year: 2021 end-page: 388 ident: b0520 article-title: Variant-proof vaccines – invest now for the next pandemic publication-title: Nature – volume: 8 start-page: 434 year: 2020 ident: b0210 article-title: Influenza A virus vaccination: immunity, protection, and recent advances toward a universal vaccine publication-title: Vaccines – volume: 16 start-page: 723 year: 2017 end-page: 736 ident: b0270 article-title: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence publication-title: Expert Rev Vac – volume: 9 year: 2021 ident: b0390 article-title: Adjuvantation of influenza vaccines to induce cross-protective immunity publication-title: Vaccines (Basel) – start-page: 1 year: 2019 end-page: 10 ident: b0325 article-title: The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity publication-title: Hum Vac Immunotherapeutics – volume: 119 start-page: 44 year: 2019 end-page: 52 ident: b0290 article-title: Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination publication-title: J Clin Virol – reference: European External Action Service (EEAS). EU – India joint call “Towards a Next Generation Influenza Vaccine to Protect Citizens Worldwide.” EEAS - European External Action Service - European Union External Action. n.d. – volume: 9 start-page: 600 year: 2018 ident: b0090 article-title: Novel platforms for the development of a universal influenza vaccine publication-title: Front Immunol – volume: 14 start-page: 237 year: 2020 end-page: 243 ident: b0305 article-title: Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines publication-title: Influenza Other Respir Viruses – year: 2019 ident: b0015 article-title: Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs publication-title: J Virol – volume: 53 start-page: 187 year: 2018 end-page: 195 ident: b0340 article-title: Harnessing immune history to combat influenza viruses publication-title: Curr Opin Immunol – reference: IVR Roadmap Development Team. Influenza Vaccines R&D Roadmap. CIDRAP. n.d. – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: b0160 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: NEJM – reference: CDC. Selecting Viruses for the Seasonal Flu Vaccine. Centers for Disease Control and Prevention; 2020. – reference: Amitai A, Sangesland M, Barnes RM, Rohrer D, Lonberg N, Lingwood D, et al. Defining and manipulating B cell immunodominance hierarchies to elicit broadly neutralizing antibody responses against influenza virus. Cell Syst 2020:S2405471220303355. – reference: CEPI. CEPI | New Vaccines For A Safer World. Coalition for Epidemic Preparedness Innovations n.d. – volume: 10 year: 2019 ident: b0245 article-title: Innovative mucosal vaccine formulations against influenza A virus infections publication-title: Front Immunol – year: 2021 ident: b0105 article-title: mRNA vaccines manufacturing: challenges and bottlenecks publication-title: Vaccine – start-page: 1 year: 2020 end-page: 15 ident: b0415 article-title: Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains publication-title: Expert Rev Vac – start-page: a038448 year: 2020 ident: b0395 article-title: Next-generation influenza vaccines publication-title: Cold Spring Harb Perspect Med – reference: [accessed May 1, 2021]. – reference: Moderna. Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines | Moderna, Inc.; 2021 – reference: Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, et al. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis 2020:ciaa706. – volume: 10 year: 2020 ident: b0240 article-title: Recombinant influenza vaccines: saviors to overcome immunodominance publication-title: Front Immunol – volume: 18 start-page: 241 year: 2020 end-page: 249 ident: b0045 article-title: Developing vaccines for SARS-CoV-2 and future epidemics and pandemics: applying lessons from past outbreaks publication-title: Health Secur – reference: [accessed May 3, 2021]. – volume: 39 start-page: 70 year: 2018 end-page: 79 ident: b0345 article-title: From original antigenic sin to the universal influenza virus vaccine publication-title: Trends Immunol – start-page: kwz227 year: 2019 ident: b0310 article-title: Distinguishing causation from correlation in the use of correlates of protection to evaluate and develop influenza vaccines publication-title: Am J Epidemiol – reference: WHO. Global Influenza Strategy 2019-2030. WHO; 2019. – volume: 19 start-page: 383 year: 2019 end-page: 397 ident: b0225 article-title: The human antibody response to influenza A virus infection and vaccination publication-title: Nat Rev Immunol – volume: 2019 year: 2009 ident: b0030 article-title: Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic publication-title: Vaccine – volume: 13 start-page: 68 year: 2021 ident: b0380 article-title: Promising adjuvants and platforms for influenza vaccine development publication-title: Pharmaceutics – volume: 14 start-page: 1840 year: 2018 end-page: 1847 ident: b0190 article-title: H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation publication-title: Hum Vac Immunotherapeutics – volume: 35 start-page: 6255 year: 2017 end-page: 6263 ident: b0495 article-title: Estimating the full public health value of vaccination publication-title: Vaccine – volume: 37 start-page: 4830 year: 2019 end-page: 4834 ident: b0460 article-title: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: methodologic considerations publication-title: Vaccine – reference: CARB-X. CARB-X. Carb-X n.d. – volume: 219 start-page: S62 year: 2019 end-page: S67 ident: b0430 article-title: Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain publication-title: J Infect Dis – start-page: a038471 year: 2020 ident: b0265 article-title: Influenza vaccines delivered in early childhood could turn antigenic sin into antigenic blessings publication-title: Cold Spring Harb Perspect Med – volume: 6 start-page: 58 year: 2018 ident: b0435 article-title: The future of influenza vaccines: a historical and clinical perspective publication-title: Vaccines – volume: 219 start-page: S97 year: 2019 end-page: S106 ident: b0025 article-title: Influenza immunization in low- and middle-income countries: preparing for next-generation influenza vaccines publication-title: J Infect Dis – reference: . – volume: 70 start-page: 2496 year: 2020 end-page: 2502 ident: b0360 article-title: Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States publication-title: Clin Infect Dis – volume: 14 start-page: 550 year: 2018 end-page: 564 ident: b0385 article-title: Adjuvanted influenza vaccines publication-title: Hum Vac Immunotherapeutics – volume: 30 start-page: 916 year: 2012 end-page: 921 ident: b0060 article-title: Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean publication-title: Vaccine – volume: 391 start-page: 1285 year: 2018 end-page: 1300 ident: b0035 article-title: Estimates of global seasonal influenza-associated respiratory mortality: a modelling study publication-title: Lancet – volume: 218 start-page: 347 year: 2018 end-page: 354 ident: b0080 article-title: A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases publication-title: J Infect Dis – volume: 22 start-page: 105 year: 2017 end-page: 111 ident: b0335 article-title: Immune history and influenza virus susceptibility publication-title: Curr Opin Virol – volume: 32 start-page: 1630 year: 2014 end-page: 1637 ident: b0140 article-title: Vaccines against sexually transmitted infections: the way forward publication-title: Vaccine – volume: 219 start-page: S107 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0185 article-title: Preparing for the next influenza pandemic: the development of a universal influenza vaccine publication-title: J Infect Dis doi: 10.1093/infdis/jiz043 – start-page: a038448 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0395 article-title: Next-generation influenza vaccines publication-title: Cold Spring Harb Perspect Med – start-page: a038471 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0265 article-title: Influenza vaccines delivered in early childhood could turn antigenic sin into antigenic blessings publication-title: Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a038471 – year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0235 article-title: Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope publication-title: Cell Host Microbe doi: 10.1016/j.chom.2019.04.003 – ident: 10.1016/j.vaccine.2021.08.010_b0135 – volume: 3 start-page: 845 year: 2014 ident: 10.1016/j.vaccine.2021.08.010_b0445 article-title: Animal models for influenza viruses: implications for universal vaccine development publication-title: Pathogens doi: 10.3390/pathogens3040845 – start-page: a038596 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0215 article-title: Systems biological analysis of immune response to influenza vaccination publication-title: Cold Spring Harb Perspect Med – year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0015 article-title: Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs publication-title: J Virol doi: 10.1128/JVI.00797-19 – volume: 116 start-page: 13474 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0230 article-title: Outflanking immunodominance to target subdominant broadly neutralizing epitopes publication-title: PNAS doi: 10.1073/pnas.1816300116 – ident: 10.1016/j.vaccine.2021.08.010_b0510 – ident: 10.1016/j.vaccine.2021.08.010_b0485 – start-page: kwz227 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0310 article-title: Distinguishing causation from correlation in the use of correlates of protection to evaluate and develop influenza vaccines publication-title: Am J Epidemiol – volume: 114 start-page: 12578 year: 2017 ident: 10.1016/j.vaccine.2021.08.010_b0200 article-title: Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1712377114 – ident: 10.1016/j.vaccine.2021.08.010_b0070 – volume: 6 start-page: 19 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0195 article-title: Efforts to improve the seasonal influenza vaccine publication-title: Vaccines doi: 10.3390/vaccines6020019 – volume: 382 start-page: 1969 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0525 article-title: Developing Covid-19 vaccines at pandemic speed publication-title: N Engl J Med doi: 10.1056/NEJMp2005630 – volume: 219 start-page: S38 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0020 article-title: Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens publication-title: J Infect Dis doi: 10.1093/infdis/jiy696 – volume: 39 start-page: 512 year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0475 article-title: Global production capacity of seasonal and pandemic influenza vaccines in 2019 publication-title: Vaccine doi: 10.1016/j.vaccine.2020.12.018 – ident: 10.1016/j.vaccine.2021.08.010_b0115 – year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0490 article-title: Funding of pharmaceutical innovation during and after the COVID-19 pandemic publication-title: JAMA doi: 10.1001/jama.2020.25384 – volume: 22 start-page: 105 year: 2017 ident: 10.1016/j.vaccine.2021.08.010_b0335 article-title: Immune history and influenza virus susceptibility publication-title: Curr Opin Virol doi: 10.1016/j.coviro.2016.12.004 – volume: 219 start-page: S97 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0025 article-title: Influenza immunization in low- and middle-income countries: preparing for next-generation influenza vaccines publication-title: J Infect Dis doi: 10.1093/infdis/jiz024 – volume: 35 start-page: 6255 year: 2017 ident: 10.1016/j.vaccine.2021.08.010_b0495 article-title: Estimating the full public health value of vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2017.09.048 – volume: 9 start-page: 1 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0175 article-title: Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011–2018 publication-title: Sci Rep doi: 10.1038/s41598-019-39276-1 – volume: 6 start-page: 58 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0435 article-title: The future of influenza vaccines: a historical and clinical perspective publication-title: Vaccines doi: 10.3390/vaccines6030058 – start-page: 1 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0420 article-title: Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection publication-title: Expert Opin Drug Discov – volume: 37 start-page: 4823 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0455 article-title: Meeting report: convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity publication-title: Vaccine doi: 10.1016/j.vaccine.2019.06.080 – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0160 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: NEJM doi: 10.1056/NEJMoa2034577 – volume: 16 start-page: 723 year: 2017 ident: 10.1016/j.vaccine.2021.08.010_b0270 article-title: Repeated annual influenza vaccination and vaccine effectiveness: review of evidence publication-title: Expert Rev Vac doi: 10.1080/14760584.2017.1334554 – volume: 38 start-page: 2751 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0450 article-title: Workshop report: optimization of animal models to better predict influenza vaccine efficacy publication-title: Vaccine doi: 10.1016/j.vaccine.2020.01.101 – ident: 10.1016/j.vaccine.2021.08.010_b0075 – ident: 10.1016/j.vaccine.2021.08.010_b0350 – volume: 19 start-page: 383 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0225 article-title: The human antibody response to influenza A virus infection and vaccination publication-title: Nat Rev Immunol doi: 10.1038/s41577-019-0143-6 – volume: 2019 year: 2009 ident: 10.1016/j.vaccine.2021.08.010_b0030 article-title: Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic publication-title: Vaccine – volume: 18 start-page: 241 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0045 article-title: Developing vaccines for SARS-CoV-2 and future epidemics and pandemics: applying lessons from past outbreaks publication-title: Health Secur doi: 10.1089/hs.2020.0043 – volume: 38 start-page: 4221 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0300 article-title: Antibody responses to influenza A(H1N1)pdm infection publication-title: Vaccine doi: 10.1016/j.vaccine.2020.04.069 – ident: 10.1016/j.vaccine.2021.08.010_b0005 – ident: 10.1016/j.vaccine.2021.08.010_b0470 – ident: 10.1016/j.vaccine.2021.08.010_b0040 – volume: 590 start-page: 386 year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0520 article-title: Variant-proof vaccines – invest now for the next pandemic publication-title: Nature doi: 10.1038/d41586-021-00340-4 – volume: 16 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0170 article-title: Beyond clinical trials: evolutionary and epidemiological considerations for development of a universal influenza vaccine publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1008583 – volume: 10 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0245 article-title: Innovative mucosal vaccine formulations against influenza A virus infections publication-title: Front Immunol doi: 10.3389/fimmu.2019.01605 – volume: 37 start-page: 4830 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0460 article-title: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: methodologic considerations publication-title: Vaccine doi: 10.1016/j.vaccine.2019.06.053 – volume: 8 start-page: 361 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0315 article-title: Prospects and challenges in the development of universal influenza vaccines publication-title: Vaccines doi: 10.3390/vaccines8030361 – volume: 8 start-page: 434 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0210 article-title: Influenza A virus vaccination: immunity, protection, and recent advances toward a universal vaccine publication-title: Vaccines doi: 10.3390/vaccines8030434 – volume: 14 start-page: 550 issue: 3 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0385 article-title: Adjuvanted influenza vaccines publication-title: Hum Vac Immunotherapeutics doi: 10.1080/21645515.2017.1415684 – volume: 8 start-page: 1745 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0100 article-title: New technologies for influenza vaccines publication-title: Microorganisms doi: 10.3390/microorganisms8111745 – volume: 219 start-page: S75 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0365 article-title: Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection publication-title: J Infect Dis doi: 10.1093/infdis/jiz017 – volume: 37 start-page: 211 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0130 article-title: Global funders consortium for universal influenza vaccine development publication-title: Vaccine doi: 10.1016/j.vaccine.2018.11.037 – ident: 10.1016/j.vaccine.2021.08.010_b0150 – volume: 19 start-page: 487 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0355 article-title: Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) publication-title: BMC Public Health doi: 10.1186/s12889-019-6713-5 – ident: 10.1016/j.vaccine.2021.08.010_b0155 – start-page: 1 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0110 article-title: Next-generation influenza vaccines: opportunities and challenges publication-title: Nat Rev Drug Discovery – volume: 9 year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0390 article-title: Adjuvantation of influenza vaccines to induce cross-protective immunity publication-title: Vaccines (Basel) – volume: 39 start-page: 70 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0345 article-title: From original antigenic sin to the universal influenza virus vaccine publication-title: Trends Immunol doi: 10.1016/j.it.2017.08.003 – ident: 10.1016/j.vaccine.2021.08.010_b0515 – year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0250 article-title: Universal influenza vaccines: progress in achieving broad cross-protection in vivo publication-title: Am J Epidemiol doi: 10.1093/aje/kwy145 – start-page: 1 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0325 article-title: The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity publication-title: Hum Vac Immunotherapeutics – volume: 24 start-page: 18 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0320 article-title: Overcoming barriers in the path to a universal influenza virus vaccine publication-title: Cell Host Microbe doi: 10.1016/j.chom.2018.06.016 – volume: 9 start-page: e02332 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0375 article-title: NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? publication-title: MBio doi: 10.1128/mBio.02332-17 – volume: 14 start-page: 678 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0180 article-title: Models for predicting the evolution of influenza to inform vaccine strain selection publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2017.1423152 – volume: 6 start-page: 142 year: 2012 ident: 10.1016/j.vaccine.2021.08.010_b0165 article-title: Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 publication-title: Influenza Other Respir Viruses doi: 10.1111/j.1750-2659.2011.00277.x – ident: 10.1016/j.vaccine.2021.08.010_b0065 – volume: 219 start-page: S62 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0430 article-title: Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain publication-title: J Infect Dis doi: 10.1093/infdis/jiy711 – volume: 19 start-page: 1305 year: 2013 ident: 10.1016/j.vaccine.2021.08.010_b0425 article-title: Cellular immune correlates of protection against symptomatic pandemic influenza publication-title: Nat Med doi: 10.1038/nm.3350 – volume: 206 start-page: S22 year: 2012 ident: 10.1016/j.vaccine.2021.08.010_b0055 article-title: 2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa—successes and challenges publication-title: J Infect Dis doi: 10.1093/infdis/jis535 – year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0105 article-title: mRNA vaccines manufacturing: challenges and bottlenecks publication-title: Vaccine doi: 10.1016/j.vaccine.2021.03.038 – ident: 10.1016/j.vaccine.2021.08.010_b0145 – ident: 10.1016/j.vaccine.2021.08.010_b0480 doi: 10.1126/scitranslmed.aaw2888 – volume: 25 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0500 article-title: Public health-driven research and innovation for next-generation influenza vaccines, European Union publication-title: Emerg Infect Dis doi: 10.3201/eid2502.180359 – volume: 30 start-page: 916 year: 2012 ident: 10.1016/j.vaccine.2021.08.010_b0060 article-title: Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean publication-title: Vaccine doi: 10.1016/j.vaccine.2011.11.092 – volume: 53 start-page: 187 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0340 article-title: Harnessing immune history to combat influenza viruses publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2018.05.010 – volume: 218 start-page: 347 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0080 article-title: A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases publication-title: J Infect Dis doi: 10.1093/infdis/jiy103 – start-page: a040964 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0280 article-title: Influenza immunization in the context of preexisting immunity publication-title: Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a040964 – volume: 70 start-page: 2496 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0360 article-title: Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States publication-title: Clin Infect Dis doi: 10.1093/cid/ciz676 – volume: 10 start-page: 1660 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0260 article-title: Age-specific differences in the dynamics of protective immunity to influenza publication-title: Nat Commun doi: 10.1038/s41467-019-09652-6 – ident: 10.1016/j.vaccine.2021.08.010_b0410 doi: 10.2139/ssrn.3586996 – volume: 13 start-page: 68 year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0380 article-title: Promising adjuvants and platforms for influenza vaccine development publication-title: Pharmaceutics doi: 10.3390/pharmaceutics13010068 – ident: 10.1016/j.vaccine.2021.08.010_b0125 – ident: 10.1016/j.vaccine.2021.08.010_b0120 – volume: 12 start-page: 519 year: 2013 ident: 10.1016/j.vaccine.2021.08.010_b0295 article-title: Immunological assessment of influenza vaccines and immune correlates of protection publication-title: Expert Rev Vac doi: 10.1586/erv.13.35 – start-page: 1 year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0085 article-title: Better, faster, stronger: mRNA vaccines show promise for influenza vaccination in older adults publication-title: Immunol Invest – volume: 9 start-page: 26 year: 2021 ident: 10.1016/j.vaccine.2021.08.010_b0095 article-title: The next generation of influenza vaccines: towards a universal solution publication-title: Vaccines doi: 10.3390/vaccines9010026 – volume: 8 start-page: 409 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0370 article-title: Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine publication-title: Vaccines doi: 10.3390/vaccines8030409 – volume: 9 start-page: 600 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0090 article-title: Novel platforms for the development of a universal influenza vaccine publication-title: Front Immunol doi: 10.3389/fimmu.2018.00600 – start-page: a038729 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0220 article-title: Immunity to influenza infection in humans publication-title: Cold Spring Harb Perspect Med – volume: 10 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0240 article-title: Recombinant influenza vaccines: saviors to overcome immunodominance publication-title: Front Immunol doi: 10.3389/fimmu.2019.02997 – ident: 10.1016/j.vaccine.2021.08.010_b0285 doi: 10.1093/infdis/jiz433 – volume: 219 start-page: S88 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0400 article-title: New vaccine design and delivery technologies publication-title: J Infect Dis doi: 10.1093/infdis/jiy745 – volume: 14 start-page: 1840 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0190 article-title: H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation publication-title: Hum Vac Immunotherapeutics doi: 10.1080/21645515.2018.1462639 – year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0255 article-title: Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies publication-title: PNAS doi: 10.1073/pnas.1920321117 – ident: 10.1016/j.vaccine.2021.08.010_b0275 doi: 10.1093/cid/ciaa706 – volume: 25 start-page: 212 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0405 article-title: Current and future influenza vaccines publication-title: Nat Med doi: 10.1038/s41591-018-0340-z – ident: 10.1016/j.vaccine.2021.08.010_b0010 – ident: 10.1016/j.vaccine.2021.08.010_b0465 – volume: 391 start-page: 1285 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0035 article-title: Estimates of global seasonal influenza-associated respiratory mortality: a modelling study publication-title: Lancet doi: 10.1016/S0140-6736(17)33293-2 – volume: 119 start-page: 44 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0290 article-title: Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination publication-title: J Clin Virol doi: 10.1016/j.jcv.2019.08.009 – volume: 14 start-page: 237 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0305 article-title: Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12706 – volume: 219 start-page: S5 year: 2019 ident: 10.1016/j.vaccine.2021.08.010_b0205 article-title: Making universal influenza vaccines: lessons from the 1918 pandemic publication-title: J Infect Dis doi: 10.1093/infdis/jiy728 – ident: 10.1016/j.vaccine.2021.08.010_b0505 – volume: 1 start-page: 254 year: 2011 ident: 10.1016/j.vaccine.2021.08.010_b0050 article-title: Influenza virus vaccines: lessons from the 2009 H1N1 pandemic publication-title: Curr Opin Virol doi: 10.1016/j.coviro.2011.08.002 – volume: 36 start-page: 6895 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0440 article-title: Workshop report: experimental animal models for universal influenza vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2018.10.024 – volume: 7 start-page: 178 year: 2018 ident: 10.1016/j.vaccine.2021.08.010_b0330 article-title: The influenza vaccine mess publication-title: J Pediatr Infectious Dis Soc doi: 10.1093/jpids/piy057 – start-page: 1 year: 2020 ident: 10.1016/j.vaccine.2021.08.010_b0415 article-title: Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains publication-title: Expert Rev Vac – volume: 32 start-page: 1630 year: 2014 ident: 10.1016/j.vaccine.2021.08.010_b0140 article-title: Vaccines against sexually transmitted infections: the way forward publication-title: Vaccine doi: 10.1016/j.vaccine.2014.01.053 |
| SSID | ssj0005319 |
| Score | 2.550478 |
| SecondaryResourceType | review_article |
| Snippet | Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future... AbstractImproved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6573 |
| SubjectTerms | Allergy and Immunology Animals Broadly protective influenza vaccines Collaboration Consortia Coronaviruses COVID-19 vaccines finance human influenza Humans Immunology Infectious diseases Influenza Influenza Vaccines Influenza, Human - epidemiology Influenza, Human - prevention & control issues and policy Medical research Orthomyxoviridae Orthomyxoviridae Infections Pandemic preparedness Pandemics Public health R&D Regulation Research & development research and development Roadmap Seasonal influenza vaccines Severe acute respiratory syndrome coronavirus 2 Stakeholders Universal influenza vaccines vaccine development Vaccines Virology Viruses |
| SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection 2013 dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1daxQxcCgFxRfR82u1SgQ5FLp3u0k2yfpWqqWIlaKtHL6EbJKTK7p39K5CffC3m9nN7lWsVnzc3RnyMZP52MwHwLPc5dJVSqTCCoNFtV2qTMFST2n4ZKjjTdnFg3di_5i_mRSTDdjtcmEwrDLK_lamN9I6vhnH3RwvZrPxh6zR5dkkOC2oJTHhl3OJXD76cSHMgzXNPRA4Reh1Fs_4ZPTNWLy-Dm4ibSt5YiLt5frpT_Zno4f2bsHNaECSnXaOt2HD1wO41raUPB_A9YN4WT6A4WFblvp8mxyts6yW22RIDtcFqwPO4CPGxDSJuaRDvwOfdkgXlkdM7ciF8CLy_P3w1QtyOjfuq1mQYPeSWdvs5LshcbXLl-Qt_huuP5NVE5pLgqlJ2hImd-F47_XR7n4aOzGktlB0lUrKRGaUssyiUvfMClca65h0VorgouB1oXEZk6ry00pI6aWj1uW2DBSoJLsHm_W89g-AeCeZ8MIUlcr5lOfGMiW9yUrqnfBTngDv9l_bWKYcu2V80V082omOC9FINo1dNPMsgVGPtmjrdFyFIDri6i4JNYhNHTTJVYjyMkS_jId_qXO9pDrTvzFoAqrH_IXH_2XQrY7_dD8ODbQpRBkIksDT_nMQD3jnY2o_P0MYWWal4rn8C4xgQgWzlhYJ3G95u99DxgV6qfTh_8_9EdzAJ1T4tNyCzdXpmX8cLLlV9aQ5qj8BP_ZEqA priority: 102 providerName: Elsevier |
| Title | A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X21010288 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X21010288 https://dx.doi.org/10.1016/j.vaccine.2021.08.010 https://www.ncbi.nlm.nih.gov/pubmed/34602302 https://www.proquest.com/docview/2582569024 https://www.proquest.com/docview/2579098417 https://www.proquest.com/docview/2636815925 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-xTSAkhKB8rDAmI6EKpKVLbNd2eEFlbCofq6qxTRUvlmO7ExOkZemQxgN_O3bstDyMjZckUnJxknPufuf7AniRmYybQrCEaaZ8UW2TCNUjicXYnVLY0Lrs4v6QDY7oh3FvHBfcqhhW2cjEWlCbqfZr5Nu452wZZ8ph-mb2I_Fdo7x3NbbQWIE1X7rMz2o-5ssQD1I39nBmBk1olo6XGTzbp92fSnvXtTMRcaji6ZNoL9dN_8KetQ7auwd3I3hE_cDt-3DDli24GdpJXrTg1n50lLegMwolqS-20OEyw6raQh00WhardjR3wrodCulILWgd-_iYOkkXNbd7AF_6qAnRQ6o06K9QI_TyoPPuFTqbKvNdzZDDwOhraHzyS6H49tVr9MmvE5cnaF6H6SIHO1EoZ_IQjvZ2D3cGSezKkGjHgnnCMWGpEkIT7RW8JZqZXGlDuNGcOXPFuw6VSQkXhZ0UjHPLDdYm07njSMHJI1gtp6VdB2QNJ8wy1StERic0U5oIblWaY2uYndA20IYfUseS5b5zxjfZxKadyvgi0rNR-o6aWdqG7oJsFmp2XEfAGmbLJiHViVDptMp1hPwyQltFQVDJTFZYpvJzWgPPdOwsbA_pRBvEgjJinYBh_mfQjWY-ysU4y9-jDc8Xp52o8P4fVdrpub-G52kuaMavuIYRJhzExb02PA5zffENCWXeYsVPrn6Ap3DbP61X8DjfgNX52bl95pDbvNiEle7vbLP-Sd1W7Ljjtf77j4Oh27_dHY4O_gAUgkR4 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIT4khKB8FQYYCSaQli2xHdtBQmjamDrWTtPoUMWLcWwXMUFalg5U_ij-Ruw4afcwNl72bJ_t5M7n39n3AfA8MQk3uWAR00z5pNomEiolkcXYNSlsaJV2sbfLOgf0_SAdLMCfJhbGu1U2OrFS1Gak_R35Gk6dLeNMOUzfjn9EvmqUf11tSmgEsdix01_OZCvfbG86_r7AeOtdf6MT1VUFIu2GmEQcExYrITTR_oCyRDOTKW0IN9rZ9G4WnKXKxISL3A5zxrnlBmuT6MxJbM6JG_cSXKbEbU0fmb5xwqWEVIVEnFlDI5rEg3nE0Nrh6k-l_VO5M0lxyBrqg3ZPPwv_hXWrM2_rFtyswSpaD9J1GxZs0YIroXzltAVXe_XDfAuW90IK7OkK6s8jusoVtIz25smxHc2NcE-IQvhTC1ofvT9OFRSMmuHuwKd11LgEIlUYdMK1Cb3cX958hY5GynxXY-QwN_oaCq38Vqj--vI16vp76eILmlRuwcjBXBTSp9yFgwvh1z1YLEaFfQDIGk6YZSrNRUKHNFGaCG5VnGFrmB3SNtCGH1LXKdJ9pY5vsvGFO5T1h0jPRukreCZxG1ZnZOOQI-Q8AtYwWzYBsE5lS3eKnUfITyO0Za14SpnIEstYfogroBsPnEXvIaRog5hR1tgqYKb_mXSpkUc5m2e-HdvwbNbsVJN_b1KFHR37PjyLM0ETfkYfRphwkBqnbbgfZH32Dwll3kLGD89ewFO41un3urK7vbvzCK77lXtwgbMlWJwcHdvHDjVO8ifVVkXw-aJ1w19X6Xuc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NISYkhKB8FQYYCSqQljWxHdtBQmhaqTb2oYltqOLFOLaLmCAtSwcqfxp_HXactHsYGy97ts92cufz7-z7AHiemISbXLCIaaZ8Um0TCZWSyGLsmhQ2tEq7uLPLNg7p-0E6WIA_TSyMd6tsdGKlqM1I-zvyLk6dLeNMOUy7w9otYq_Xfzv-EfkKUv6ltSmnEURky05_OfOtfLPZc7x-gXH_3cH6RlRXGIi0G24ScUxYrITQRPvDyhLNTKa0IdxoZ9-7GXGWKhMTLnI7zBnnlhusTaIzJ705J27cK3CVu3a_x8T6KfcSUhUVcSYOjWgSD-bRQ92j1Z9K-2dzZ57ikEHUB_CefS7-C_dW51__FtysgStaC5J2GxZs0YJroZTltAVLO_UjfQs6eyEd9nQFHcyju8oV1EF780TZjuZGuDNEIRSqBa2P3jenChBGzXB34NMaatwDkSoMOuXmhF5-6PReoeORMt_VGDn8jb6Goiu_Faq_vnyNtv0ddfEFTSoXYeQgLwqpVO7C4aXw6x4sFqPCPgBkDSfMMpXmIqFDmihNBLcqzrA1zA5pG2jDD6nrdOm-asc32fjFHcn6Q6Rno_TVPJO4DaszsnHIF3IRAWuYLZtgWKe-pTvRLiLkZxHaslZCpUxkiWUs9-MK9MYDZ917OCnaIGaUNc4K-Ol_Jl1u5FHO5plvzTY8mzU7NeXfnlRhRye-D8_iTNCEn9OHESYcvMZpG-4HWZ_9Q0KZt5bxw_MX8BSWnFaQ25u7W4_gul-4xxk4W4bFyfGJfewA5CR_Uu1UBJ8vWzX8BVDNf9I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Research+and+Development+%28R%26D%29+roadmap+for+influenza+vaccines%3A+Looking+toward+the+future&rft.jtitle=Vaccine&rft.au=Moore%2C+Kristine+A&rft.au=Ostrowsky%2C+Julia+T&rft.au=Kraigsley%2C+Alison+M&rft.au=Mehr%2C+Angela+J&rft.date=2021-10-29&rft.pub=Elsevier+Limited&rft.issn=0264-410X&rft.eissn=1873-2518&rft.volume=39&rft.issue=45&rft.spage=6573&rft_id=info:doi/10.1016%2Fj.vaccine.2021.08.010&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X21X00448%2Fcov150h.gif |